RVNC - Revance falls after Mizuho downgrades citing too high guidance
2024-01-29 09:00:19 ET
NASDAQ: RVNC 3.5%More on Revance Therapeutics
- Revance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines
- Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript
- Revance Therapeutics expects to achieve positive adj EBITDA in 2025
- Public Citizen petitions FDA for stricter warnings against Botox, similar drugs
- Seeking Alpha’s Quant Rating on Revance Therapeutics